A detailed history of Northern Trust Corp transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 685,167 shares of KURA stock, worth $6.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
685,167
Previous 663,621 3.25%
Holding current value
$6.17 Million
Previous $13.7 Million 2.01%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$18.57 - $23.23 $400,109 - $500,513
21,546 Added 3.25%
685,167 $13.4 Million
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $538,609 - $706,060
-30,725 Reduced 4.43%
663,621 $13.7 Million
Q1 2024

May 14, 2024

SELL
$13.42 - $23.53 $207,661 - $364,103
-15,474 Reduced 2.18%
694,346 $14.8 Million
Q4 2023

Feb 13, 2024

BUY
$7.58 - $14.38 $33,670 - $63,875
4,442 Added 0.63%
709,820 $10.2 Million
Q3 2023

Nov 13, 2023

BUY
$8.44 - $11.86 $662,472 - $930,915
78,492 Added 12.52%
705,378 $6.43 Million
Q2 2023

Aug 11, 2023

SELL
$9.62 - $13.99 $60,759 - $88,360
-6,316 Reduced 1.0%
626,886 $6.63 Million
Q1 2023

May 15, 2023

SELL
$10.71 - $14.6 $1.37 Million - $1.87 Million
-128,032 Reduced 16.82%
633,202 $7.74 Million
Q4 2022

Feb 13, 2023

BUY
$11.23 - $16.9 $1.4 Million - $2.1 Million
124,422 Added 19.54%
761,234 $9.45 Million
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $36,390 - $58,933
3,030 Added 0.48%
636,812 $8.7 Million
Q2 2022

Aug 12, 2022

SELL
$10.71 - $18.33 $211,693 - $362,310
-19,766 Reduced 3.02%
633,782 $11.6 Million
Q1 2022

May 13, 2022

SELL
$11.78 - $16.98 $86,147 - $124,174
-7,313 Reduced 1.11%
653,548 $10.5 Million
Q4 2021

Feb 08, 2022

SELL
$12.22 - $19.57 $1.08 Million - $1.74 Million
-88,673 Reduced 11.83%
660,861 $9.25 Million
Q3 2021

Nov 15, 2021

SELL
$15.42 - $21.72 $241,245 - $339,809
-15,645 Reduced 2.04%
749,534 $14 Million
Q2 2021

Aug 13, 2021

BUY
$20.85 - $29.88 $1.02 Million - $1.46 Million
48,766 Added 6.81%
765,179 $16 Million
Q1 2021

May 12, 2021

SELL
$24.75 - $39.14 $862,537 - $1.36 Million
-34,850 Reduced 4.64%
716,413 $20.3 Million
Q4 2020

Feb 11, 2021

BUY
$29.0 - $41.62 $2.18 Million - $3.13 Million
75,088 Added 11.1%
751,263 $24.5 Million
Q3 2020

Nov 16, 2020

SELL
$16.3 - $30.64 $403,294 - $758,094
-24,742 Reduced 3.53%
676,175 $20.7 Million
Q2 2020

Aug 14, 2020

BUY
$7.95 - $18.81 $1.94 Million - $4.6 Million
244,302 Added 53.5%
700,917 $11.4 Million
Q1 2020

May 14, 2020

BUY
$6.45 - $14.04 $152,445 - $331,835
23,635 Added 5.46%
456,615 $4.54 Million
Q4 2019

Feb 14, 2020

SELL
$12.97 - $15.94 $423,275 - $520,201
-32,635 Reduced 7.01%
432,980 $5.95 Million
Q3 2019

Nov 13, 2019

BUY
$14.75 - $20.87 $1.18 Million - $1.67 Million
80,137 Added 20.79%
465,615 $7.06 Million
Q2 2019

Aug 13, 2019

BUY
$14.71 - $19.79 $106,632 - $143,457
7,249 Added 1.92%
385,478 $7.59 Million
Q1 2019

May 13, 2019

BUY
$13.73 - $16.87 $40,833 - $50,171
2,974 Added 0.79%
378,229 $6.28 Million
Q4 2018

Feb 12, 2019

SELL
$10.6 - $17.49 $21,857 - $36,064
-2,062 Reduced 0.55%
375,255 $5.27 Million
Q3 2018

Nov 14, 2018

BUY
$16.65 - $21.85 $963,985 - $1.27 Million
57,897 Added 18.13%
377,317 $6.6 Million
Q2 2018

Sep 18, 2018

SELL
$14.8 - $18.8 $32,293 - $41,021
-2,182 Reduced 0.68%
319,420 $5.81 Million
Q2 2018

Aug 14, 2018

BUY
$14.8 - $18.8 $978,191 - $1.24 Million
66,094 Added 25.87%
321,602 $5.85 Million
Q1 2018

May 09, 2018

BUY
$14.5 - $23.4 $303,934 - $490,487
20,961 Added 8.94%
255,508 $4.79 Million
Q4 2017

Feb 14, 2018

BUY
$13.5 - $16.65 $333,018 - $410,722
24,668 Added 11.75%
234,547 $3.59 Million
Q3 2017

Nov 13, 2017

BUY
$6.05 - $14.95 $1.27 Million - $3.14 Million
209,879
209,879 $3.14 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $603M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.